Table 3a.
Between-treatment p-values for the baseline visit are calculated using an anova model that includes fixed factor treatment
| Assessment/Treatment | Air blast sensitivity | Change from baseline | Between-Treatment p-value | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean | SD | Median | Min. | Max. | n | Mean | SD | Median | Min. | Max. | p-val | vs. Test-A | vs. Test-B | vs. Control | ||
| Baseline | Test-A | 49 | 1.93 | 0.59 | 2.00 | 1.0 | 3.0 | 0 | – | – | – | – | – | – | – | n.s. | n.s. |
| Test-B | 52 | 1.93 | 0.59 | 2.00 | 1.0 | 3.0 | 0 | – | – | – | – | – | – | n.s. | – | n.s. | |
| Control | 50 | 1.97 | 0.63 | 2.00 | 1.0 | 3.0 | 0 | – | – | – | – | – | – | n.s. | n.s. | – | |
| Post-Prophy | Test-A | 49 | 1.07 | 0.64 | 1.00 | 0.0 | 3.0 | 49 | −0.86 | 0.62 | −1.00 | −2.5 | 0.5 | <0.0001 | – | n.s. | <0.0001 |
| Test-B | 52 | 1.07 | 0.62 | 1.00 | 0.0 | 2.5 | 52 | −0.87 | 0.71 | −1.00 | −2.5 | 0.0 | <0.0001 | n.s. | – | <0.0001 | |
| Control | 50 | 1.97 | 0.70 | 2.00 | 0.0 | 3.0 | 50 | 0.00 | 0.35 | 0.00 | −1.0 | 1.0 | n.s. | <0.0001 | <0.0001 | – | |
| Day 28 | Test-A | 49 | 0.98 | 0.62 | 1.00 | 0.0 | 3.0 | 49 | −0.95 | 0.66 | −1.00 | −2.5 | 0.5 | <0.0001 | – | n.s. | <0.0001 |
| Test-B | 52 | 0.99 | 0.55 | 1.00 | 0.0 | 2.5 | 52 | −0.94 | 0.68 | −1.00 | −2.5 | 0.5 | <0.0001 | n.s. | – | <0.0001 | |
| Control | 48 | 2.03 | 0.67 | 2.00 | 0.5 | 3.0 | 48 | 0.03 | 0.47 | 0.00 | −1.0 | 1.0 | n.s. | <0.0001 | <0.0001 | – | |
Between-treatment p-values for the subsequent visits are calculated using an ancova model that includes fixed factor treatment, and the baseline air blast sensitivity score as a covariate.
n.s. = non-significant.